SA
Sami Alam
Associate Director (Ctl) - Adult And Pediatric Gastroenterology & Hepatology (Rare Disease) at Mirum Pharmaceuticals,
View Sami's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Apr 2021 - Present · 3 years and 9 months
Associate Director (Ctl) - Adult And Pediatric Gastroenterology & Hepatology (Rare Disease)
Feb 2024 - Present · 11 months
Clinical Trial Liaison (Ctl) - Adult And Pediatric Gastroenterology & Hepatology (Rare Disease)
Apr 2022 - Feb 2024 · 1 years and 10 months
Medical Science Liaison (Msl) - Adult And Pediatric Gastroenterology & Hepatology (Rare Disease)
Apr 2021 - Apr 2022 · 1 years
Company Details
201-500 Employees
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX). Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.
Year Founded
2018
Social Media
LinkedinFacebookTwitter
Industry
Pharmaceutical Manufacturing
HQ Location
950 Tower Lane Suite 1050 Foster City, CA 94404, US
Keywords
--
Discover More About Cleveland Clinic

Find verified contacts of Sami Alam in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.